Abstracts tagged "biologic response modifiers and anti-TNF therapy"

Abstract Number: 1500 • 2019 ACR/ARP Annual Meeting
Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?
Santiago Rodrigues-Manica¹, Alexandre Sepriano ², Fernando Pimentel-Santos ¹, Nélia Gouveia ³, Anabela Barcelos ⁴, Jaime Branco ¹, Miguel Bernardes ⁵, Raquel Miriam-Ferreira ⁵, Elsa Vieira-Sousa ⁶, Sofia Barreira ⁶, Filipe Vinagre ⁷, Raquel Roque ⁷, Helena Santos ⁸, Nathalie Madeira ⁸, João Rovisco ⁹, Alexandra Daniel ⁹ and Sofia Ramiro ¹⁰, ¹CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, ²Leiden University Medical Center, Leiden, Netherlands, ³CEDOC, NOVA-Medical School, Lisbon, Portugal, Lisboa, Portugal, ⁴Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, ⁵Rheumatology, Centro Hospitalar de São João, Porto, Portugal, Porto, Portugal, ⁶Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ⁷Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ⁸Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ⁹Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Coimbra, Portugal, ¹⁰Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands
Background/Purpose: Over the last years, and mostly due to lack of alternatives, it has been common practice to start a second TNF inhibitor (TNFi) in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].